Liang Dan, Qi Yulin, Liu Lu, Chen Zhaoxia, Tang Shiyun, Tang Jianyuan, Chen Nianzhi
TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Department of Ophthalmology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Chin Med. 2023 Oct 12;18(1):130. doi: 10.1186/s13020-023-00840-7.
Jin-Gui-Shen-Qi Wan (JGSQ) has been used in China for thousands of years to treat various ailments, including frequent urination, blurred vision, and soreness in the waist and knees. It has traditional therapeutic advantages in improving eye diseases.
Clinical studies have confirmed the therapeutic efficacy of JGSQ in improving diabetes and vision; however, its efficacy and pharmacological effects in treating diabetic retinopathy (DR) remain unclear. Therefore, the aim of this study was to investigate the specific pharmacological effects and potential mechanisms of JGSQ in improving DR through a db/db model.
db/db mice were given three different doses of orally administered JGSQ and metformin for 8 weeks, and then PAS staining of the retinal vascular network patch, transmission electron microscopy, H&E staining, and TUNEL staining were performed to determine the potential role of JGSQ in improving DR-induced neuronal cell apoptosis. Furthermore, network pharmacology analysis and molecular docking were carried out to identify the main potential targets of JGSQ, and the efficacy of JGSQ in improving DR was evaluated through western blotting and immunofluorescence staining, revealing its mechanism of action.
According to the results from H&E, TUNEL, and PAS staining of the retinal vascular network patch and transmission electron microscopy, JGSQ does not have an advantage in improving the abnormal morphology of vascular endothelial cells, but it has a significant effect on protecting retinal ganglion cells from apoptosis. Through network pharmacology and molecular docking, AKT, GAPDH, TNF, TP53, and IL-6 were identified as the main core targets of JGSQ. Subsequently, through western blot and immunofluorescence staining, it was found that JGSQ can inhibit HIF-1α, promote p-AKT expression, and inhibit TP53 expression. At the same time, inhibiting the release of inflammatory factors protects retinal ganglion cells and improves apoptosis in DR.
These results indicated that in the db/db DR mouse model, JGSQ can inhibit the expression of inflammatory cytokines and protect retinal ganglion cells from apoptosis, possibly by modulating the Akt/HIF-1α pathway.
金匮肾气丸在中国已应用数千年,用于治疗多种疾病,包括尿频、视力模糊以及腰膝酸痛。它在改善眼部疾病方面具有传统治疗优势。
临床研究已证实金匮肾气丸在改善糖尿病和视力方面的治疗效果;然而,其在治疗糖尿病视网膜病变(DR)中的疗效和药理作用仍不清楚。因此,本研究的目的是通过db/db模型研究金匮肾气丸改善DR的具体药理作用和潜在机制。
给db/db小鼠口服三种不同剂量的金匮肾气丸和二甲双胍,持续8周,然后进行视网膜血管网络片的PAS染色、透射电子显微镜检查、苏木精-伊红染色和TUNEL染色,以确定金匮肾气丸在改善DR诱导的神经元细胞凋亡中的潜在作用。此外,进行网络药理学分析和分子对接以确定金匮肾气丸的主要潜在靶点,并通过蛋白质免疫印迹法和免疫荧光染色评估金匮肾气丸改善DR的疗效,揭示其作用机制。
根据视网膜血管网络片的苏木精-伊红染色、TUNEL染色和PAS染色以及透射电子显微镜检查结果,金匮肾气丸在改善血管内皮细胞异常形态方面没有优势,但在保护视网膜神经节细胞免于凋亡方面有显著作用。通过网络药理学和分子对接,确定AKT、GAPDH、TNF、TP53和IL-6为金匮肾气丸的主要核心靶点。随后,通过蛋白质免疫印迹法和免疫荧光染色发现,金匮肾气丸可抑制HIF-1α,促进p-AKT表达,并抑制TP53表达。同时,抑制炎症因子的释放可保护视网膜神经节细胞并改善DR中的细胞凋亡。
这些结果表明,在db/db DR小鼠模型中,金匮肾气丸可抑制炎性细胞因子的表达并保护视网膜神经节细胞免于凋亡,可能是通过调节Akt/HIF-1α途径实现的。